Literature DB >> 24704591

EGF/EGFR axis contributes to the progression of cholangiocarcinoma through the induction of an epithelial-mesenchymal transition.

Audrey Clapéron1, Martine Mergey1, Thanh Huong Nguyen Ho-Bouldoires1, Danijela Vignjevic2, Dominique Wendum3, Yves Chrétien1, Fatiha Merabtene4, Alexandra Frazao1, Valérie Paradis5, Chantal Housset1, Nathalie Guedj5, Laura Fouassier6.   

Abstract

BACKGROUND & AIMS: Epithelial-mesenchymal transition (EMT) is a cellular process involved in cancer progression. The first step of EMT consists in the disruption of E-cadherin-mediated adherens junctions. Cholangiocarcinoma (CCA), a cancer with a poor prognosis due to local invasion and metastasis, displays EMT features. EGFR, a receptor tyrosine kinase, plays a major role in CCA progression. The aim of the study was to determine if EMT is induced by EGFR in CCA cells.
METHODS: In vivo, the expression of E-cadherin was analysed in CCA tumours of 100 patients and correlated with pathological features and EGFR expression, and in a xenograft model in mice treated with gefitinib, an inhibitor of EGFR. In vitro, the regulation of EMT by EGFR was investigated in CCA cell lines.
RESULTS: In human CCA, a cytoplasmic localization of E-cadherin occurred in 50% of the tumours was associated with the peripheral type of CCA, tumour size, the presence of satellite nodules and EGFR overexpression. In xenografted tumours, E-cadherin displayed a cytoplasmic pattern whereas the treatment of mice with gefitinib restored the membranous expression of E-cadherin. In vitro, EGF induced scattering of CCA cells that resulted from the disruption of adherens junctions. Internalization and decreased expression of E-cadherin, as well as nuclear translocation of β-catenin, were observed in EGF-treated CCA cells. In these cells, EMT-transcription factors (i.e., Slug and Zeb-1) and mesenchymal markers (i.e., N-cadherin and α-SMA) were induced, favoring cell invasiveness through cytoskeleton remodeling. All these effects were inhibited by gefitinib.
CONCLUSIONS: The EGF/EGFR axis triggers EMT in CCA cells highlighting the key role of this pathway in CCA progression.
Copyright © 2014 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cholangiocarcinoma; E-cadherin; EGF; EGFR; Invasion; Migration

Mesh:

Substances:

Year:  2014        PMID: 24704591     DOI: 10.1016/j.jhep.2014.03.033

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  46 in total

Review 1.  Cholangiocarcinoma 2020: the next horizon in mechanisms and management.

Authors:  Jesus M Banales; Jose J G Marin; Angela Lamarca; Pedro M Rodrigues; Shahid A Khan; Lewis R Roberts; Vincenzo Cardinale; Guido Carpino; Jesper B Andersen; Chiara Braconi; Diego F Calvisi; Maria J Perugorria; Luca Fabris; Luke Boulter; Rocio I R Macias; Eugenio Gaudio; Domenico Alvaro; Sergio A Gradilone; Mario Strazzabosco; Marco Marzioni; Cédric Coulouarn; Laura Fouassier; Chiara Raggi; Pietro Invernizzi; Joachim C Mertens; Anja Moncsek; Sumera Rizvi; Julie Heimbach; Bas Groot Koerkamp; Jordi Bruix; Alejandro Forner; John Bridgewater; Juan W Valle; Gregory J Gores
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-06-30       Impact factor: 46.802

Review 2.  Cholangiocarcinoma.

Authors:  Paul J Brindley; Melinda Bachini; Sumera I Ilyas; Shahid A Khan; Alex Loukas; Alphonse E Sirica; Bin Tean Teh; Sopit Wongkham; Gregory J Gores
Journal:  Nat Rev Dis Primers       Date:  2021-09-09       Impact factor: 65.038

3.  Emerging roles of GALNT5 on promoting EGFR activation in cholangiocarcinoma: a mechanistic insight.

Authors:  Marutpong Detarya; Worachart Lert-Itthiporn; Panupong Mahalapbutr; Methus Klaewkla; Supannika Sorin; Kanlayanee Sawanyawisuth; Atit Silsirivanit; Wunchana Seubwai; Chaisiri Wongkham; Norie Araki; Sopit Wongkham
Journal:  Am J Cancer Res       Date:  2022-09-15       Impact factor: 5.942

4.  PF-2341066 combined with celecoxib promotes apoptosis and inhibits proliferation in human cholangiocarcinoma QBC939 cells.

Authors:  Chen Chen; Dinghua Yang; Qinghua Zeng; Liang Luo; Chengzhi Cai
Journal:  Exp Ther Med       Date:  2018-03-20       Impact factor: 2.447

Review 5.  Precision medicine in cholangiocarcinoma.

Authors:  Antonio Pellino; Fotios Loupakis; Massimiliano Cadamuro; Vincenzo Dadduzio; Matteo Fassan; Maria Guido; Umberto Cillo; Stefano Indraccolo; Luca Fabris
Journal:  Transl Gastroenterol Hepatol       Date:  2018-07-12

6.  Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA).

Authors:  Jesus M Banales; Vincenzo Cardinale; Guido Carpino; Marco Marzioni; Jesper B Andersen; Pietro Invernizzi; Guro E Lind; Trine Folseraas; Stuart J Forbes; Laura Fouassier; Andreas Geier; Diego F Calvisi; Joachim C Mertens; Michael Trauner; Antonio Benedetti; Luca Maroni; Javier Vaquero; Rocio I R Macias; Chiara Raggi; Maria J Perugorria; Eugenio Gaudio; Kirsten M Boberg; Jose J G Marin; Domenico Alvaro
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-04-20       Impact factor: 46.802

Review 7.  Molecular Mechanisms Driving Cholangiocarcinoma Invasiveness: An Overview.

Authors:  Simone Brivio; Massimiliano Cadamuro; Luca Fabris; Mario Strazzabosco
Journal:  Gene Expr       Date:  2017-10-25

Review 8.  Targeted therapies for extrahepatic cholangiocarcinoma: preclinical and clinical development and prospects for the clinic.

Authors:  Massimiliano Cadamuro; Alberto Lasagni; Angela Lamarca; Laura Fouassier; Maria Guido; Samantha Sarcognato; Enrico Gringeri; Umberto Cillo; Mario Strazzabosco; Jose Jg Marin; Jesus M Banales; Luca Fabris
Journal:  Expert Opin Investig Drugs       Date:  2021-02-23       Impact factor: 6.206

9.  Probing the Anti-Cancer Potency of Sulfated Galactans on Cholangiocarcinoma Cells Using Synchrotron FTIR Microspectroscopy, Molecular Docking, and In Vitro Studies.

Authors:  Boonyakorn Boonsri; Kiattawee Choowongkomon; Buabarn Kuaprasert; Thanvarin Thitiphatphuvanon; Kittiya Supradit; Apinya Sayinta; Jinchutha Duangdara; Tawut Rudtanatip; Kanokpan Wongprasert
Journal:  Mar Drugs       Date:  2021-04-30       Impact factor: 5.118

10.  Inhibition of Mast Cell-Derived Histamine Decreases Human Cholangiocarcinoma Growth and Differentiation via c-Kit/Stem Cell Factor-Dependent Signaling.

Authors:  Christopher Johnson; Victoria Huynh; Laura Hargrove; Lindsey Kennedy; Allyson Graf-Eaton; Jennifer Owens; Jerome P Trzeciakowski; Kyle Hodges; Sharon DeMorrow; Yuyan Han; Lucas Wong; Gianfranco Alpini; Heather Francis
Journal:  Am J Pathol       Date:  2015-11-18       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.